Background {#Sec1}
==========

Traumatic brain injury (TBI) is a major public health problem in both the civilian and military populations as TBI has now become a prominent injury in war zones. Of the 1.7 million new TBIs that are sustained annually in the United States \[[@CR1]\], 53,000 result in death \[[@CR2]\] while an additional 125,000 leave the affected people with long-term behavioral deficits \[[@CR3]\]. Overall, about 3 million Americans are currently suffering with chronic effects of TBI \[[@CR4]\]. Additionally, it is estimated that 17--30 % of soldiers returning for Iraq and Afghanistan have suffered TBIs \[[@CR5], [@CR6]\]. Development of more effective clinical treatments is necessary to reduce the healthcare and financial burden of TBI. Such development requires basic experimentation into the mechanisms underlying TBI.

Primary damage to cells by TBI may be irreversible and lead to immediate cell death, however, delayed or secondary cell death that is caused by a cascade of cellular and molecular processes initiated by the trauma \[[@CR7]--[@CR10]\] may be reduced or prevented if an effective neuroprotective strategy is employed. Development of such a strategy requires an understanding of the molecular environment in the injured brain so that deleterious molecules and processes can be identified and inhibited. A step towards understanding the molecular response to TBI is examining gene expression profiles following the injury.

Microarray technology allows for examination of thousands of genes in one assay. The key to using this technology is interpreting the resulting gene expression patterns and using the interpreted data to guide further study. The development of advanced bioinformatic analysis tools have aided in deciphering microarray data. One such tool is the Ingenuity Pathway Analysis (IPA) software program which uses a database built from published scientific literature to draw direct and indirect interactions between genes and to assign genes to specific biological functions, canonical pathways, and networks \[[@CR11]\]. IPA also features a strong network building component that allows for the creation and analysis of networks composed of any genes of interest (GOI). We have previously devised a method for using the initial information that IPA provides and subsequent network analysis to determine which genes are most significant to the inflammatory response following neuronal injury unilateral controlled cortical impact (CCI) in the rat \[[@CR12]\]. This analysis results in a gene interaction hierarchy (GIH) where genes of interest are ranked based on the number of interactions they have with each other. The theory behind the analysis is that a gene that interacts with more genes in a particular set of genes has the potential to influence that set of genes the most.

The current study uses gene expression profiling and bioinformatic analysis to examine the cell death gene response 24 h following unilateral CCI. One significant finding of our previous study was that while inflammatory gene expression was induced on the ipsilateral side of the brain following TBI, there was a suppression of inflammatory genes contralateral to the injury \[[@CR12]\]. We believe that this endogenous anti-inflammatory response may hold clues for the development of anti-inflammatory treatments for TBI and other acute brain injuries. Inflammation resulting from many different types of acute brain injuries, including TBI and ischemic stroke, has been linked to subsequent neuronal cell death \[[@CR13]--[@CR16]\]. By extension, we believe that understanding the post-TBI expression of genes involved in acute cell death will provide clues for the development of neuroprotective strategies.

Methods {#Sec2}
=======

Animals {#Sec3}
-------

All animals used in these studies were treated humanely and with regard for alleviation of suffering and pain and all protocols involving animals were approved by the IACUCs of Morehouse School of Medicine and/or The Georgia Institute of Technology prior to the initiation of experimentation. Adult male Sprague--Dawley rats (290--300 g; Charles River Laboratories International, Inc., USA) were housed individually in standard plastic cages in a temperature-controlled room (22 ± 2 °C) on a 12 h reverse light--dark cycle. Food and water were provided ad libitum.

Controlled cortical impact {#Sec4}
--------------------------

Under isoflurane anesthesia, rats received a unilateral controlled cortical impact (CCI/TBI) using the Pittsburgh Precision Instruments, Inc. device. A craniotomy was made with the center 4 mm posterior and 3--4 mm lateral to bregma using a 6 mm diameter trephan drill bit. The impact was done at an angle of 15° from vertical with a velocity of 3 m/s to a depth of 2 mm using a 5 mm diameter impact tip. These parameters were chosen to produce a moderate injury \[[@CR17]\]. The rats were sacrificed 24 h post-injury and the brains were removed for RNA isolation or histology.

RNA preparation and GeneChip analysis {#Sec5}
-------------------------------------

The ipsilateral hemi-brain tissue at the site of the injury, the corresponding contralateral hemi-brain tissue, and naïve (control) brain tissue (*n =* 3 for each) were used for RNA isolation. Total RNA was extracted with TRIzol Reagent (Life Technologies, Rockville, MD, USA) and cleaned (RNAqueous Kit, Ambion, Austin, TX, USA). The RNA was prepared for microarray hybridization with the GeneChip® 3′ IVT Express Kit (Affymetrix Inc., Santa Clara, CA, USA) aRNA amplification procedure. Briefly, total RNA was reverse transcribed to synthesize first-strand cDNA containing a T7 promoter sequence. The single-stranded cDNA was converted into a double-stranded DNA template for transcription. The reaction employed DNA polymerase and RNase H to simultaneously degrade the RNA and synthesize second-strand cDNA. *In vitro* transcription generated multiple copies of biotin-modified aRNA from the double-stranded cDNA templates (this was the amplification step). aRNA Purification removed unincorporated NTPs, salts, enzymes, and inorganic phosphate to improve the stability of the biotin-modified aRNA. Finally, the labeled aRNA was fragmented to prepare the sample for hybridization to GeneChip® 3′ expression arrays \[[@CR18]\]. Following fragmentation, 15 μg of the biotinylated cRNA was hybridized to an Affymetrix Rat Genome 230 2.0 GeneChip. The chips were hybridized at 45 °C for 16 h, and then washed, stained with streptavidin--phycoerythrin and scanned according to manufacturing guidelines.

Microarray data analysis {#Sec6}
------------------------

Data analysis was performed using Affymetrix Expression Console™ software that supports probe set summarization and CHP file generation of 3′ expression using the MAS5 Statistical algorithm. Affymetrix microarrays contain the hybridization, labeling and housekeeping controls that help determine the success of the hybridizations. The Affymetrix Expression Analysis algorithm uses the Tukey's biweight estimator to provide a robust mean Signal value and the Wilcoxon's rank test to calculate a significance or p-value and Detection call (present, marginal or absent) for each probe set. The Detection p-value is calculated using a Discrimination Score \[R\] for all probes. The Discrimination Score is a basic property of a probe pair that describes its ability to detect its intended target. It measures the target-specific intensity differences of the probe pair (perfect match (PM) -- mismatch (MM)) relative to its overall hybridization intensity (PM + MM). Background estimation is provided by a weighted average of the lowest 2 % of the feature intensities. Mismatch probes are utilized to adjust the perfect match (PM) intensity. Linear scaling of the feature level intensity values, using the trimmed mean, is the default to make the means equal for all arrays being analyzed. False-negative and false-positive rates are minimized by subtracting nonspecific signal from the PM probe intensities and performing an intensity-dependent normalization at the probe set level. Three chips were used for each experimental group: ipsilateral, contralateral and naïve control. The dataset produced by the Affymetrix software contains gene identifiers, corresponding expression values, and determination of whether genes are confirmed as present, marginal or absent. Previous principle component analysis of the raw datasets demonstrated that ipsilateral, contralateral and naïve clustered together by injury status and each group was well isolated from the other two groups \[[@CR12]\]. The data were analyzed in Microsoft Excel for calculation of fold change and whether the genes were confirmed as present in the tissue sample. Genes in the injured brain that increased or decreased in expression by 2-fold or more compared to controls and were present in either all 3 ipsilateral samples or all 3 contralateral samples were identified. The gene datasets that were generated were ipsilateral vs. naïve (TBI-I) and contralateral vs. naïve (TBI-C) fold changes.

Ingenuity pathway analysis {#Sec7}
--------------------------

The gene datasets were analyzed between December 3, 2014 and January 8, 2015 using Ingenuity Pathway Analysis (Ingenuity® Systems, [www.ingenuity.com](http://www.ingenuity.com)) and overlaid onto a global molecular network developed from information contained in the Ingenuity Knowledge Base. The right-tailed Fisher's Exact Test was used to determine the likelihood that the association between a set of experimental genes and a given biological function or pathway is not due to random chance \[[@CR19]\]. In general, p-values less than 0.05 indicate a statistically significant, non-random association. The functions, canonical pathways, and gene networks that were most significant to the dataset were identified. Gene expression profiles were overlaid on the canonical pathway and gene network figures to reveal similarities and dissimilarities in their gene expression patterns. Gene networks were also created using Ingenuity Knowledge Base to further understand specific interactions between our genes of interest.

TBI-I/TBI-C ratio {#Sec8}
-----------------

We used the following formulas to calculate the ratio of TBI-I to TBI-C fold changes: (1) Gene increased on both sides (TBI-I \> TBI-C): ratio = (TBI-I)/(TBI-C); (2) Gene decreased on both sides (TBI-I \> TBI-C): ratio = 1/\[(TBI-I)/(TBI-C)\]; (3) Gene decreased on both sides (TBI-I \< TBI-C): ratio = −1/\[(TBI-C)/(TBI-I)\]; (4) Gene increased ipsilaterally and decreased contralaterally: ratio = (TBI-I)/-\[1/(TBI-C)\]; (5) Gene decreased ipsilaterally and increased contralaterally: ratio = (TBI-C)/\[1/(TBI-I)\].

Histology {#Sec9}
---------

At 24 h post injury, rats were anesthetized with an intraperitoneal injection of a ketamine:xylazine:acetylpromazine cocktail (50:10:1.67 mg/kg respectively) and perfused transcardially with saline followed by cold 4 % paraformaldehyde solution in PBS for 30 min. Brains were quickly removed and cryoprotected in 30 % sucrose. The brains were then frozen in OCT mounting medium and stored until sectioning. Coronal sections of 20 μm thickness were cryosectioned from the perilesional brain area of each animal. Sections were mounted on slides which were stored at −80 °C until further processed. Fluoro-Jade® B (AG310, Millipore, Billerica, MA) labeling was performed as previously described \[[@CR20]\]. TUNEL staining was performed using the TUNEL reaction mixture from the In Situ Cell Death Detection Kit, TMR red (12 156 792 910, Roche Diagnostics, Mannheim, Germany). Briefly, slide-mounted sections were post-fixed with 4 % paraformaldehyde for 15 min followed by a 10 min incubation in a 20 μg/mL proteinase K solution in 100 mM Tris HCl (pH 8.0) and 50 mM EDTA. The sections were then incubated for 60 min at 37 °C in the TUNEL reaction mixture. Phosphate buffered saline was used to rinse the sections after each step. A Zeiss fluorescence microscope equipped with a CCD camera (Carl Zeiss Microimaging, Inc., Thornwood, NY) was used to capture digital images of the sections.

Real-time polymerase chain reaction (PCR) {#Sec10}
-----------------------------------------

RNA was extracted as above and quantified using the Nanodrop 2000c (Thermo Scientific, Waltham, MA). Equal amounts of ipsilateral, contralateral, and naïve RNA (*n =* 2 for each) were converted to cDNA using the iScript™ Reverse Transcription Supermix for RT-qPCR (170--8840, Bio-Rad Laboratories, Inc., Hercules, CA). The resulting product was diluted 1:100 with RNase-free sterile water. The diluted product was used in the real-time PCR analysis using the Quantitect SYBR® Green PCR Kit (204143, Qiagen, Hilden, Germany), custom oligo primers for SPP1, HSPB1, STAT3, CCND1, and GAPDH (reference gene) (Life Technologies, Rockville, MD), and a Bio-Rad CFX96™ Real-Time System mounted on a C1000™ Thermal Cycler. All steps were carried out according to manufacturer's protocols. The real-time PCR results were analyzed using the ΔΔCt method where ΔCt1 = Ct (Target A‐exp) -- Ct (GAPDH-exp); ΔCt2 = Ct (Target A‐naïve) --Ct (GAPDH‐naïve); and ΔΔCt = ΔCt1 -- ΔCt2. The normalized target gene expression level was given by 2^-ΔΔCt^. The results were compared pairwise using a one-tail *T*-test assuming equal variance. Differences were considered significant when *p \<* 0.05.

Results {#Sec11}
=======

Functional analysis {#Sec12}
-------------------

To begin understanding the cell death gene response following TBI, we first looked at the biological functions associated with our datasets. Analysis of the top 15 molecular and cellular functions associated with the TBI-I (ipsilateral vs. naïve) and TBI-C (contralateral vs. naïve) datasets in IPA showed that cell death and survival (CD) was the second ranked TBI-I function that is also ranked in the top 7 functions for TBI-C (Fig. [1a](#Fig1){ref-type="fig"}, [b](#Fig1){ref-type="fig"}). Also ranked in the top 7 molecular and cellular functions for both datasets are cellular growth and proliferation, cellular assembly and organization, cellular function and maintenance, cellular development, and cell morphology. Cellular movement and cell-to-cell signaling and interaction are ranked in the top 7 only for TBI-I and TBI-C, respectively.Fig. 1Overall functional analysis. Analysis of the top 15 molecular and cellular functions determined by IPA for the TBI-I (ipsilateral vs. naïve) dataset (**a**) and the TBI-C (contralateral vs. naïve) dataset (**b**) showed that cell death and survival was a top ranked function on both sides of the brain

Histology {#Sec13}
---------

To examine cell death histologically, we chose to look at the cortical area adjacent to the impact site so we could observe the cellular response to the injury in all layers of the cortex. This is not possible at the impact site because of the resulting injury cavity. Fluoro-Jade® B (FJB) staining showed a dense distribution of damaged neurons throughout all layers of the cortex near the sight of impact (Fig. [2a](#Fig2){ref-type="fig"}, [b](#Fig2){ref-type="fig"}). Damaged neurons were also detected in the hippocampus ipsilateral to the injury (Fig. [2d](#Fig2){ref-type="fig"}). These neurons were sparsely distributed in the hippocampal CA regions. No FJB staining was detected in the cortex (Fig. [2c](#Fig2){ref-type="fig"}) or hippocampus (Fig. [2e](#Fig2){ref-type="fig"}) contralateral to the injury.Fig. 2Fluoro-Jade® B staining of the cortex and hippocampus. Fluoro-Jade® B (FJB) staining showed a dense distribution of damaged neurons throughout all layers of the cortex near the sight of impact (**a**, **b**). Damaged neurons were also detected in the hippocampus ipsilateral to the injury (**d**). These neurons were sparsely distributed in the hippocampal CA regions. No FJB staining was detected in either brain region contralateral to the injury (C: cortex; E: hippocampus). *FJB: green; Scale bars: 200 μm (* ***a*** *,* ***c*** *-* ***e*** *), 100 μm (* ***b*** *)*

TUNEL staining showed distribution of injured cells in the cortex similar to FJB as they were distributed throughout all layers of the cortex (Fig. [3a](#Fig3){ref-type="fig"}, [b](#Fig3){ref-type="fig"}). However, no TUNEL staining was detected in the ipsilateral hippocampus (Fig. [3d](#Fig3){ref-type="fig"}), suggesting that the neuronal damage in that region had not yet progressed to apoptosis. No TUNEL was observed in the contralateral cortex (Fig. [3c](#Fig3){ref-type="fig"}) or hippocampus (Fig. [3e](#Fig3){ref-type="fig"}).Fig. 3TUNEL staining of the cortex and hippocampus. TUNEL staining showed distribution of injured cells in the cortex similar to FJB as they were distributed throughout all layers of the cortex (**a**, **b**). However, no TUNEL staining was detected in the ipsilateral hippocampus (**d**). No TUNEL was observed on the contralateral side of the brain (C: cortex; E: hippocampus). *TUNEL: red; Scale bars: 200 μm (* ***a*** *,* ***c*** *-* ***e*** *), 100 μm (* ***b*** *)*

Cell death gene expression patterns {#Sec14}
-----------------------------------

Focusing on the CD genes in our datasets, we determined that 902 CD genes had a greater than 2-fold change in expression. Of these genes, 361 CD genes changed uniquely on the ipsilateral side of the brain. 317 of those genes (88 %) increased while 44 genes (12 %) decreased in expression (Fig. [4a](#Fig4){ref-type="fig"}). 136 CD genes changed uniquely on the contralateral side of the brain and, in contrast to what we observed on the ipsilateral side, only 34 genes (25 %) increased while 102 genes (75 %) decreased in expression (Fig. [4b](#Fig4){ref-type="fig"}).Fig. 4Breakdown of CD genes based on increased and decreased expression. **a** 361 CD genes changed uniquely on the ipsilateral side of the brain and 88 % (317 genes) of those increased in expression. **b** 136 CD genes changed uniquely on the contralateral side of the brain and 75 % (102 genes) of those decreased in expression. **c** There were 405 genes that changed more than 2-fold on both sides of the brain. Eighty-two percent of them (332 genes) changed similarly while the remaining 18 % (73 genes) changed differently (TBI-I/TBI-C ratio \>2; see text)

There were 405 CD genes that changed on both the ipsilateral and contralateral sides of the brain. In order to determine whether these common genes changed differently on one side of the brain compared to the other, we calculated the ratio of the TBI-I fold change to the TBI-C fold change. Those genes that had a TBI-I/TBI-C ratio greater than 2 were determined to have changed differently. We observed that 332 of the common CD genes (82 %) changed similarly (TBI-I/TBI-C ratio \< 2; Fig. [4c](#Fig4){ref-type="fig"}). Of the genes that changed similarly, 242 genes (60 %) increased in expression and 90 genes (22 %) decreased in expression. The remaining 73 common CD genes (18 %) changed differently (TBI-I/TBI-C ratio \> 2) (Fig. [4c](#Fig4){ref-type="fig"}). Table [1](#Tab1){ref-type="table"} shows the 73 common CD genes that changed differently. These genes span all cellular compartments (extracellular space, plasma membrane, cytoplasm, and nucleus) with diverse molecule types. The expression of all these genes was lower on the contralateral side of the brain with the exception of 3 genes, DNAJB6, TRIM54 and PSIP1 (negative TBI-I/TBI-C ratio). Because of their different expression patterns, these 73 genes became our first group of genes of interest (GOI; Table [1](#Tab1){ref-type="table"}). Notable genes given their high TBI-I/TBI-C ratio included SPP1, TIMP1, LCN2, SERPINA3, KCNN4, HSPB1, RDX, Slpi, ATRX, DNAJB6, NAA15, SMARCA4, STAT3, and THOC2.Table 1Genes that change differently on each side of the brainGene symbolEntrez gene nameTBI-I fold changeTBI-C fold changeTBI-I/TBI-C ratioMolecular type*Extracellular Space* SPP1secreted phosphoprotein 137.9052.37015.994cytokine TIMP1TIMP metallopeptidase inhibitor 138.4862.10118.318cytokine CPceruloplasmin (ferroxidase)27.8388.4773.284enzyme FGL2fibrinogen-like 216.7934.0174.180peptidase LCN2lipocalin 271.8243.89518.440transporterSERPINA3serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 358.4882.50923.311other*Plasma Membrane* CD44CD44 molecule (Indian blood group)15.5582.3996.485enzyme EHD4EH-domain containing 42.361−2.0564.854enzyme SDC1syndecan 113.6812.5665.332enzyme KCND2potassium voltage-gated channel, Shal-related subfamily, member 2−2.792−7.5852.717ion channel KCNN4potassium intermediate/small conductance calcium-activated channel, subfamily N, member 43.088−9.42929.117ion channelCAMK2N1calcium/calmodulin-dependent protein kinase II inhibitor 1−11.813−23.8242.017kinase EGFRepidermal growth factor receptor6.7732.3742.853kinase PTPRFprotein tyrosine phosphatase, receptor type, F−6.365−20.4923.219phosphatase IL6STinterleukin 6 signal transducer2.307−3.2837.574transmembrane receptor CD68CD68 molecule4.3652.0072.175other HLA-Amajor histocompatibility complex, class I, A9.2963.6572.542otherPMEPA1prostate transmembrane protein, androgen induced 12.682−2.9377.877other*Cytoplasm* CYP1B1cytochrome P450, family 1, subfamily B, polypeptide 110.9984.8082.287enzyme KIF3Akinesin family member 3A−5.083−11.7542.312enzyme MX1MX dynamin-like GTPase 128.1777.3263.846enzyme PDE4Bphosphodiesterase 4B, cAMP-specific5.6022.3592.375enzyme RND3Rho family GTPase 32.864−2.9718.509enzyme SRXN1sulfiredoxin 16.3062.4022.625enzyme CARD11caspase recruitment domain family, member 117.3432.8922.539kinaseCSNK2A1casein kinase 2, alpha 1 polypeptide2.992−2.7508.228kinase EIF5Beukaryotic translation initiation factor 5B−3.044−8.7662.880translation regulator RASA1RAS p21 protein activator (GTPase activating protein) 12.392−2.1055.035transporter AHI1Abelson helper integration site 12.243−2.8976.498other CISD2CDGSH iron sulfur domain 2−7.833−19.0122.427other CMIPc-Maf inducing protein−3.778−13.7633.643other CtdsplCTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like−7.271−36.8865.073other HSPB1heat shock 27 kDa protein 146.9222.63917.780other KIFAP3kinesin-associated protein 3−2.281−7.8313.433other LCP1lymphocyte cytosolic protein 1 (L-plastin)6.0822.7992.173other LSP1lymphocyte-specific protein 111.7162.1405.475otherPHLDA1pleckstrin homology-like domain, family A, member 15.1292.1602.375other RDXradixin4.828−5.27425.463other Slpisecretory leukocyte peptidase inhibitor82.9083.11926.582other Tpm3tropomyosin 32.592−2.7157.037other TRIM54tripartite motif containing 54−4.426−2.032−2.178other*Nucleus* SETD8SET domain containing (lysine methyltransferase) 82.029−3.9307.974enzyme TOP2Atopoisomerase (DNA) II alpha 170 kDa2.260−2.4065.438enzyme CDK11Acyclin-dependent kinase 11A−4.290−14.8723.467kinase GSK3Bglycogen synthase kinase 3 beta−2.733−6.6352.428kinase SRPK2SRSF protein kinase 2−5.614−23.5894.202kinase THRAthyroid hormone receptor, alpha−2.799−11.5184.115ligand-dependent nuclear receptor ATRXalpha thalassemia/mental retardation syndrome X-linked2.091−5.96412.471transcription regulator BTG2BTG family, member 2−2.220−5.8032.614transcription regulator CCAR1cell division cycle and apoptosis regulator 1−2.943−11.6483.958transcription regulator CCND1cyclin D12.152−2.0274.362transcription regulator CEBPDCCAAT/enhancer binding protein (C/EBP), delta11.2712.0375.533transcription regulator DEKDEK proto-oncogene−3.006−7.3522.446transcription regulator DNAJB6DnaJ (Hsp40) homolog, subfamily B, member 6−4.3835.614−24.606transcription regulator KLF13Kruppel-like factor 13−2.006−4.5822.284transcription regulator KLF6Kruppel-like factor 66.0032.8652.095transcription regulator NAA15N(alpha)-acetyltransferase 15, NatA auxiliary subunit3.605−3.75113.522transcription regulator NFIXnuclear factor I/X (CCAAT-binding transcription factor)−2.548−8.1123.184transcription regulator PA2G4proliferation-associated 2G4, 38 kDa−2.702−5.7832.140transcription regulatorSMARCA4SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 42.521−7.71219.442transcription regulator STAT3signal transducer and activator of transcription 3 (acute-phase response factor)4.219−3.77115.910transcription regulator TBL1XR1transducin (beta)-like 1 X-linked receptor 12.587−2.1345.521transcription regulator TCF4transcription factor 4−2.216−4.6252.087transcription regulator TPRtranslocated promoter region, nuclear basket protein2.212−2.7286.034transporter Brd4bromodomain containing 4−3.528−15.2024.309other CDT1chromatin licensing and DNA replication factor 13.098−2.2957.110otherGADD45Ggrowth arrest and DNA-damage-inducible, gamma3.191−2.3847.607other PSIP1PC4 and SFRS1 interacting protein 1−2.6632.113−5.627other Rbm25RNA binding motif protein 25−5.547−16.2132.923other THOC2THO complex 22.119−4.88610.353other*Unknown* EIF3Ceukaryotic translation initiation factor 3, subunit C−4.369−9.0722.076translation regulator Nos1apnitric oxide synthase 1 (neuronal) adaptor protein−2.698−5.7172.119other RASSF4Ras association (RalGDS/AF-6) domain family member 44.2892.1062.037otherTBI-I/TBI-C Ratio: Gene increased on both sides (TBI-I \> TBI-C): ratio = (TBI-I)/(TBI-C); Gene decreased on both sides (TBI-I \> TBI-C): ratio = 1/\[(TBI-I)/(TBI-C)\]; Gene decreased on both sides (TBI-I \< TBI-C): ratio = −1/\[(TBI-C)/(TBI-I)\]; Gene increased ipsilaterally and decreased contralaterally: ratio = (TBI-I)/-\[1/(TBI-C)\]; Gene decreased ipsilaterally and increased contralaterally: ratio = (TBI-C)/\[1/(TBI-I)\]

Canonical pathway analysis {#Sec15}
--------------------------

We used canonical pathway and network analysis in IPA to identify genes in our datasets that were potentially most relevant to the observed CD gene response. We defined potential GOI, in this context, as those genes that either changed in expression uniquely on one side of the brain, or were one of the 73 common genes that changed differently (Table [1](#Tab1){ref-type="table"}). GOI were identified by comparing the genes in the canonical pathway and gene networks to the list of unique TBI-I or TBI-C CD genes with the genes from Table [1](#Tab1){ref-type="table"} added to each list and identifying the overlapping genes. Canonical pathways in IPA are well-characterized metabolic and cell signaling pathways derived from information found in specific journal articles, review articles, text books, and KEGG Ligand \[[@CR21]\]. Fig. [5](#Fig5){ref-type="fig"} shows the apoptosis signaling canonical pathway with all relevant gene families, groups and complexes expanded to show the member genes. This pathway was chosen because apoptosis is a key process in cell death following TBI \[[@CR22]--[@CR24]\]. By overlaying the relative expression values of potential GOI for TBI-I (Fig. [5a](#Fig5){ref-type="fig"}) and TBI-C (Fig. [5b](#Fig5){ref-type="fig"}), we were able to identify 9 GOI that were increased (BCL2A1 (Bfl-1 in pathway), CASP3, CASP7, CDK1 (Cdc2), IKBKB, MAP4K4, MCL1, NFKB2, and TNFRSF1A) in the TBI-I dataset, 3 GOI that decreased (ACIN1 (Acinus), BAX and KRAS) and 1 GOI that increased (MAPK8 (JNK1)) in the TBI-C dataset.Fig. 5Canonical pathway analysis. The apoptosis signaling pathway with all gene families, groups and complexes expanded to show the member genes and showing the relative expression values of potential GOI for TBI-I (**a**) and TBI-C (**b**) included in this pathway. *red: relative increase in expression; green: relative decrease in expression; white: no change in expression; gold connections and outlines: expansion of gene families, groups and complexes in the original pathway*

Gene network analysis {#Sec16}
---------------------

In contrast to canonical pathways, which are relatively immutable in IPA, gene networks are generated *de novo* in IPA based on the list of genes that are imported. IPA takes "seed" molecules from the gene list, searches the Ingenuity Knowledge Base, and uses a network algorithm to draw connections between molecules based on biological function \[[@CR25]\]. In order to generate the networks, we performed an IPA core analysis on the TBI-I and TBI-C CD datasets. IPA scores the networks in order to rank them according to their degree of relevance to the network eligible molecules in the dataset \[[@CR25]\]. The top 6 scoring networks for each dataset were used to identify GOI.

Five of the top 6 networks for TBI-I and all 6 networks for TBI-C have cell death and survival as their top associated biological function (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Only TBI-I network 4 does not have cell death and survival as one of the top 3 associated biological functions. Figure [6](#Fig6){ref-type="fig"} shows networks 2 and 4 (Table [2](#Tab2){ref-type="table"}) as examples of the TBI-I analysis. Figure [7](#Fig7){ref-type="fig"} shows networks 2 and 4 (Table [3](#Tab3){ref-type="table"}) as examples of the TBI-C analysis. (The other networks are available as supplemental materials (Additional files [1](#MOESM1){ref-type="media"} and [2](#MOESM2){ref-type="media"}).) Like the canonical pathway analysis, all relevant gene families, groups and complexes were expanded to show the member genes. The relative TBI-I (Fig. [6](#Fig6){ref-type="fig"}) and TBI-C (Fig. [7](#Fig7){ref-type="fig"}) gene expression values of potential GOI were overlaid on these networks and additional GOI were identified. Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} show the resulting GOI that were identified through this analysis. For TBI-I, a total of 110 GOI were found in these networks, 22 of which were previously identified (Table [4](#Tab4){ref-type="table"}). Thus, 88 additional GOI were identified for TBI-I. For TBI-C, 38 additional GOI were identified as 28 of the 66 GOI found had been previously identified (Table [5](#Tab5){ref-type="table"}). The most prevalent molecular types for TBI-I were transcription regulators, unspecified enzymes, kinases, and undefined molecules. Kinases transcription regulators, unspecified enzymes, and undefined molecules were most prevalent in the TBI-C analysis.Table 2The top 6 gene networks associated with the TBI-I datasetNetwork IDMolecules in networkScoreFocus moleculesTop diseases and functions1**CADM1, CALB1, CBFB, CDCA7L, CMIP,** Cytochrome bc1**,** cytochrome-c oxidase**, DAB2, DEDD, FGF9, FLNA, FYN, GCLC, GCLM, GFAP, GFRA1, ITGA6, JDP2, MAOA, MED14, MGEA5, NFE2L1, NFE2L2, NPTX1, NRP1, PDHA1, PDLIM7, RET,** Rnr**, RPS24, RTN4, SLC18A2,** Sos**, STK17B, TAF4B**4631Cell Death and Survival, Drug Metabolism, Molecular Transport2**AMOT, ANXA1, API5, ATF3, ATG12, BAG3, CCNA2,** Cdc2**, CDK1, CDK2, CDKN1B, ETV5, FGFR3, FN1, GJA1,** Hedgehog**, LATS1, MCL1, MCM2, MCM8, MLLT4, MMS22L, NAA15,** Patched**, PIK3C2A, PKP2, PSMA7, RAB35, RPRM, SPIN1, TAGLN2, THOC2, TJP2, UNC5B, XPO1**4632Cell Death and Survival, Cell Cycle, Reproductive System Development and Function3**AHCTF1, AKAP12,** amylase**, BCL11A, CA4, CACNA1G, CCND1, CLCN7, CREB1, CREBBP, CSF1, CSRNP1, CTNNB1, DES,** Histone h3**,** IKK (complex)**, ITPR2, KLF6, KPNB1, MITF, MTMR1, NFIX, PRKD3, PTGR1, RAI14,** RNA polymerase II**, RRM2, SENP2, SMAD4, SMARCA4, SUDS3, TBL1XR1, TGM2, THRA, ZBTB18**4331Cell Death and Survival, Organismal Survival, Gene Expression4**ABCA1, ALB, ALDH1A2, BTG2, Ccl2, Ccl7, CD36, CEBPB,** chemokine**, CREM, CXCL3, DUSP5, EGR2, FGF2, FGL2, FOSL1,** FSH**, Hmgb2 (includes others), HMOX1,** IL1**,** IL12 (family)**, IL6R, ITGB2, KLF4, MAPK9, NEK6, NEK7, PDE4B,** Pld**, PRKCI, PTGS2, SPP1, THBD, TLR4, WNT5A**4230Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking5**ACSL5, AGTR2, AMFR, AVP, CAMK2N1, CAPRIN1, CHSY1, CUL5, DCK, ELAVL1,** Endothelin**, GMCL1,** GNRH**,** Insulin**, MAP4K4, MSI2,** MTORC1**, NEO1, OPA1,** Proinsulin**, PTGER3,** Relaxin**, RNF2, SLC2A3, SMAD7, STAG1, TACR1, TCEB3, TMEM123, TRAF6, WAPAL, WFS1, WTAP, ZMYM2, ZNF280B**4129Cell Death and Survival, Cardiovascular System Development and Function, Hereditary Disorder626 s Proteasome**, ARL11, BCL2L1, CAMK1G, CAMK2D, CASP3, CAV1, CISD2, CLASP1, CLN5, DLG4, EN2, ENC1,** Esr1-Esr1-estrogen-estrogen**, FBXO9, G2E3,** Hsp70**,** Hsp90**, HSP90AB1, IDE, KIF1B, MDM2, PCDH15, PGR, PI4K2A, PRDM2, PSEN1, SGPL1, SNCA, SPTBN1,** SRC (family)**, SRPK2, TMEM109, TRIM2, VPS41**4030Cell Death and Survival, Cancer, Neurological DiseaseBold= \> Gene included in the datasetNote: Some of the nodes in the original networks represent gene groups, complexes or families that, when expanded, contain more potential GOITable 3The top 6 gene networks associated with the TBI-C datasetNetwork IDMolecules in networkScoreFocus moleculesTop diseases and functions1**ACER2, ACIN1, ACVR1C, ALDH1A2, ARHGEF7, BCL11B,** caspase**, CBFB, CD38, CD44, CLCN3, CUL5, DPYD, EEF1A2, FGL2,** Fibrinogen**, ITGB1, MAP3K1, MAP3K8, MAPK8, MAPK9, MIF, MTDH, PAK1, PRDX6,** Rac**, RAD23B, SPARC,** Srebp**, TNKS2, TTLL1, VCL, WNT5A, ZBTB18, ZYX**5031Cell Death and Survival, Cellular Movement, Ophthalmic Disease2**ABCA1, AURKAIP1, BRINP1, BTG2, CACNA1G, CAV1, CCND1, CDK2, DCK, GCLC,** Histone h3**,** Histone h4**,** Insulin**, IRAK1, KMT2A, LCN2, MAFG, MTMR1,** P110**, PIAS1, PPARGC1B,** Pro-inflammatory Cytokine**,** Ras homolog**, RBM5,** RNA polymerase II**, SBF1, SETD8, SLC18A2, SMARCA2, SOX2, STAT1, TRPM7, ZBTB7A, ZMYND11, ZNF148**4428Cell Death and Survival, Gene Expression, Cellular Growth and Proliferation3**ADNP, AHI1, ANKS1B, ARL6IP1, CDK11A, CXCL12, DNAJB6, ENC1,** estrogen receptor**, FBXO9, FBXW7, FGFR3, G2E3,** Hdac**,** HSP**,** Hsp90**, HSP90AA1, HSP90AB1, HSPB1, KLF9, KLF13, LINGO1, MED1, MED14,** mediator**, PA2G4, PGR, PPP3CB, RNF4, STUB1, THRA,** TRAP/Media**, TUFM,** Ubiquitin**, VPS41**4328Cell Death and Survival, Post-Translational Modification, Protein Folding4**A2M, ACACA, AKT2, ALDH1A1,** Alp**,** AMPK**, ATG12, ATP1A1, BSG, CA3, EIF5B, ENTPD5, FGF9, FGFR1,** Focal adhesion kinase**, FOXO1, KRAS, MAP1B, MEF2A,** Mlc**, NLK, NTRK3, PALLD, PDPK1, PITX2, PPP3R1, PRKAA1, PRKCD, PSMA7, RASSF4, RPS24, Serbp1,** Sfk**, STK17B, TAOK1**4130Cell Death and Survival, Carbohydrate Metabolism, Cellular Development5ACAC**, AP2B1, APAF1,** APC-AXIN-GSK3β**, ATP2A2, ATP2B1, ATP2B2, BAX,** Ca2 ATPase**,** calpain**, CAST, CDH13,** Cytochrome bc1**,** cytochrome C**,** cytochrome-c oxidase**, DDIT4, DNM1L, GBX2,** glutathione peroxidase**, GSK3B, ITSN1, KCND2, LMO4, MAFB, MAOA, MFN1,** Mitochondrial complex 1**, MTF2, NCS1, NDUFAB1, NFE2L1, OPA1, PACS2, PEX11B, PRKAA2**3926Cell Death and Survival, Cell Cycle, Cellular Compromise6Ap1**, ARHGAP1, ARL6IP5, CCDC86, CCND2, CEBPD,** Cg**, COL1A1, DACH1,** FSH**,** Growth hormone**,** Gsk3**, IGFBP3,** Lh**, MGEA5, NEO1, PDHA1, PPP2R1A, PRLR, PSIP1, PURA, RAB27A, RPRM, RSF1, SMAD4, SMAD7,** Smad1/5/8**,** Smad2/3**, SP1, SPP1, TAF4B,** Tgf beta**, TIMP1, TNRC6A, ZMYM2**3926Cell Death and Survival, Tissue Development, Cellular Growth and ProliferationBold= \> Gene included in the datasetNote: Some of the nodes in the original networks represent gene groups, complexes or families that, when expanded, contain more potential GOIFig. 6Examples of TBI-I networks. TBI-I CD networks 2 (**a**) and 4 (**b**) (see Table [2](#Tab2){ref-type="table"}) with all gene families, groups and complexes expanded to show the member genes and showing the relative expression values of potential GOI for TBI-I. *red: relative increase in expression; green: relative decrease in expression; white: no change in expression; gold connections and outlines: expansion of gene families, groups and complexes in the original network*Fig. 7Examples of TBI-C networks. TBI-C CD networks 2 (**a**) and 4 (**b**) (see Table [3](#Tab3){ref-type="table"}) with all gene families, groups and complexes expanded to show the member genes and showing the relative expression values of potential GOI for TBI-C. *red: relative increase in expression; green: relative decrease in expression; white: no change in expression; gold connections and outlines: expansion of gene families, groups and complexes in the original network*Table 4Identification of genes of interest from TBI-I network analysisNetwork IDGOI foundTotal \# of GOIOverlap with previous analysesNet \# of GOITop molecular types1**CALB1, CDCA7L,** *CMIP* **, DAB2, FLNA, GCLM, GFAP, NFE2L2, PDLIM7**918undefined2**ANXA1, ATF3, BAG3, CCNA2,** *CDK1* **, CDKN1B, ETV5, FN1, LATS1,** *MCL1* **, MCM2, MCM8, MMS22L,** *NAA15* **, RAB35, SPIN1, TAGLN2,** *THOC2* **, TJP2, UNC5B**20416undefined, enzymes, and kinases3**BCL11A,** *CCND1* **, CREB1, CREBBP, CSRNP1, DES,** *IKBKB* **, ITPR2,** *KLF6* **, KPNB1, MITF,** *NFIX* **, PTGR1, RAI14, RRM2, SENP2,** *SMARCA4* **, SUDS3,** *TBL1XR1* **, TGM2,** *THRA*21714transcription regulators and enzymes4**ALB,** *BTG2* **, Ccl2, CCL3L3, CCL4, Ccl6, Ccl7, CD36, CEBPB, CREM, CX3CL1, CXCL3, Cxcl9, DUSP5, EGR2, FGF2,** *FGL2* **, FOSL1, HMOX1, IL1B, IL6R, ITGB2, KLF4, NEK6,** *PDE4B* **, PTGS2,** *SPP1* **, TLR4**28424cytokines, transcription regulators, and transmembrane receptors5**ACSL5,** *CAMK2N1* **, CHSY1, ELAVL1,** *MAP4K4* **, MSI2, PTGER3, TCEB3, TMEM123, TRAF6, WFS1**1129undefined and kinases6**ARL11, CAMK1G,** *CASP3* **,** *CISD2* **, CLN5, DNAJB6,** *DNAJB9* **, FGR, HCK, HSPA1A/HSPA1B, HSPA2, HSPA9, HSPB8, MDM2, PCDH15, PI4K2A, PRDM2, SGPL1, SNCA,** *SRPK2* **, TMEM109**21417undefined, kinases, and transcription regulatorsItalics= \> gene of interest also found in a previous analysis; Bold= \> GOI unique to this analysisTable 5Identification of genes of interest from TBI-C network analysisNetwork IDGOI foundTotal \# of GOIOverlap with previous analysesNet \# of GOITop molecular types1*ACIN1* **, ACVR1C,** *CD44* **, DPYD,** *FGL2* **,** *MAPK8* **, MTDH, RAD23B, TTLL1**945enzymes and kinases2**AURKAIP1,** *BTG2* **,** *CCND1* **,** *LCN2* **, MAFG, PIK3CD, PIK3R2,** *RND3* **,** *SETD8* **, SOX2, TRPM7, ZMYND11, ZNF148**1358transcription regulators, kinases, and enzymes3*AHI1* **,** *CDK11A* **, CDK19,** *DNAJB6* **, HSP90AA1,** *HSPB1* **,** *KLF13* **, LINGO1, MED1,** *PA2G4* **, PPP3CB,** *THRA* **, TUFM**1376transcription regulators, undefined, and kinases4*EIF5B* **, ENTPD5, FOXO1,** *KRAS* **, MEF2A, PALLD, PRKAA2, PTK2B,** *RASSF4* **, Serbp**1037undefined, transcription regulators, enzymes, and kinases5**ATP2A2, ATP2B2,** *BAX* **, CDH13, GBX2,** *GSK3B* **,** *KCND2* **, MAFB, MFN1, NDUFAB1,** *PRKAA2*1147transporters, kinases, enzymes, and undefined6**CCDC86, CCND2,** *CEBPD* **,** *GSK3B* **, PRLR,** *PSIP1* **, RSF1, SP1,** *SPP1* **,** *TIMP1*1055transcription regulators, undefined, and cytokinesItalics= \> gene of interest also found in a previous analysis; Bold= \> GOI unique to this analysis

Compiling the gene interaction hierarchy (GIH) {#Sec17}
----------------------------------------------

TBI-I: By combining the GOI identified through canonical pathway and network analysis with those in Table [1](#Tab1){ref-type="table"}, we identified a total of 170 GOI. In order to determine which genes might be most relevant to CD, we ranked these genes relative to each other by the number of direct interactions each had with the other GOI. Our analysis showed that 145 of the GOI formed an interconnected network, leaving 25 "orphan" genes (see Additional file [3](#MOESM3){ref-type="media"}). Genes having 1st order connections with more than 10 % of the other genes within the main GOI network (\>14 connections) were considered "primary" in this analysis (see Fig. [8](#Fig8){ref-type="fig"} for an example). Genes having connections with 5 %--10 % of the other genes (8--14 connections) were considered "secondary" (see Additional file [4](#MOESM4){ref-type="media"} for an example) and those with connections with less than 5 % of the other genes (\<8 connections) were considered "peripheral". The resultant GIH is displayed in Table [6](#Tab6){ref-type="table"}.Fig. 8An example of calculating the number of direct connections for the TBI-I GOI network. In IPA, the gene in question was selected (MDM2 in this example). Then, its direct connections were selected by right clicking on MDM2 and using the "select nearest neighbors" option (highlighted in purple). A list of the selected genes was exported and MDM2 was removed from the list (upper right corner). The remaining genes were counted (26 in this example) and MDM2 was ranked in the TBI-I gene interaction hierarchy (primary tier) by this numberTable 6TBI-I Gene interaction hierarchy (GIH)Gene symbolEntrez gene nameFold changeCellular compartmentMolecular type*Primary* ATF3activating transcription factor 312.027Nucleustranscription regulator  *CCND1*cyclin D12.152Nucleustranscription regulator CEBPBCCAAT/enhancer binding protein (C/EBP), beta3.366Nucleustranscription regulator CREB1cAMP responsive element binding protein 12.666Nucleustranscription regulator CREBBPCREB binding protein2.421Nucleustranscription regulator MDM2MDM2 proto-oncogene, E3 ubiquitin protein ligase2.01Nucleustranscription regulator NFE2L2nuclear factor, erythroid 2-like 22.452Nucleustranscription regulator  *SMARCA4*SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 42.521Nucleustranscription regulator  *STAT3*signal transducer and activator of transcription 3 (acute-phase response factor)4.219Nucleustranscription regulator CDK1cyclin-dependent kinase 12.105Nucleuskinase  *CSNK2A1*casein kinase 2, alpha 1 polypeptide2.992Cytoplasmkinase  *EGFR*epidermal growth factor receptor6.773Plasma Membranekinase  *GSK3B*glycogen synthase kinase 3 beta−2.733Nucleuskinase  *CD44*CD44 molecule (Indian blood group)15.558Plasma Membraneenzyme FN1fibronectin 13.97Extracellular Spaceenzyme TRAF6TNF receptor-associated factor 6, E3 ubiquitin protein ligase2.163Cytoplasmenzyme CASP3caspase 3, apoptosis-related cysteine peptidase2.535Cytoplasmpeptidase ELAVL1ELAV like RNA binding protein 13.275Cytoplasmother*Secondary*  *CEBPD*CCAAT/enhancer binding protein (C/EBP), delta11.271Nucleustranscription regulator CREMcAMP responsive element modulator2.165Nucleustranscription regulator EGR2early growth response 22.271Nucleustranscription regulator FOSL1FOS-like antigen 15.875Nucleustranscription regulator KLF4Kruppel-like factor 4 (gut)2.057Nucleustranscription regulator MITFmicrophthalmia-associated transcription factor4.755Nucleustranscription regulator  *TCF4*transcription factor 4−2.216Nucleustranscription regulator HSPA1A/HSPA1Bheat shock 70 kDa protein 1A3.137Cytoplasmenzyme MCM2minichromosome maintenance complex component 22.57Nucleusenzyme PTGS2prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)3.106Cytoplasmenzyme IL1Binterleukin 1, beta5.166Extracellular Spacecytokine  *SPP1*secreted phosphoprotein 137.905Extracellular Spacecytokine CDKN1Bcyclin-dependent kinase inhibitor 1B (p27, Kip1)3.732Nucleuskinase IKBKBinhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta2.127Cytoplasmkinase KPNB1karyopherin (importin) beta 13.173Nucleustransporter MCL1myeloid cell leukemia 13.25Cytoplasmtransporter  *THRA*thyroid hormone receptor, alpha−2.799Nucleusligand-dependent nuclear receptor CASP7caspase 7, apoptosis-related cysteine peptidase2.579Cytoplasmpeptidase BAG3BCL2-associated athanogene 34.045Cytoplasmother CCNA2cyclin A22.633Nucleusother GFAPglial fibrillary acidic protein3.011Cytoplasmother HSPA9heat shock 70 kDa protein 9 (mortalin)2.666Cytoplasmother  *HSPB1*heat shock 27 kDa protein 146.922Cytoplasmother SNCAsynuclein, alpha (non A4 component of amyloid precursor)−2.169Cytoplasmother*Peripheral* ACSL5acyl-CoA synthetase long-chain family member 5−2.361Cytoplasmenzyme ANXA1annexin A13.535Plasma Membraneenzyme CHSY1chondroitin sulfate synthase 12.873Cytoplasmenzyme  *CP*ceruloplasmin (ferroxidase)27.838Extracellular Spaceenzyme  *EHD4*EH-domain containing 42.361Plasma Membraneenzyme GCLMglutamate-cysteine ligase, modifier subunit2.019Cytoplasmenzyme HMOX1heme oxygenase (decycling) 19.778Cytoplasmenzyme MCM8minichromosome maintenance complex component 82.027Nucleusenzyme  *MX1*MX dynamin-like GTPase 128.177Cytoplasmenzyme  *PDE4B*phosphodiesterase 4B, cAMP-specific5.602Cytoplasmenzyme RAB35RAB35, member RAS oncogene family2.086Cytoplasmenzyme RRM2ribonucleotide reductase M23.34Nucleusenzyme  *SDC1*syndecan 113.681Plasma Membraneenzyme  *SETD8*SET domain containing (lysine methyltransferase) 82.029Nucleusenzyme SGPL1sphingosine-1-phosphate lyase 13.108Cytoplasmenzyme  *SRXN1*sulfiredoxin 16.306Cytoplasmenzyme TGM2transglutaminase 23.574Cytoplasmenzyme  *TOP2A*topoisomerase (DNA) II alpha 170 kDa2.26Nucleusenzyme BCL11AB-cell CLL/lymphoma 11A (zinc finger protein)−2.38Nucleustranscription regulator  *BTG2*BTG family, member 2−2.22Nucleustranscription regulator  *CCAR1*cell division cycle and apoptosis regulator 1−2.943Nucleustranscription regulator CSRNP1cysteine-serine-rich nuclear protein 12.821Nucleustranscription regulator  *DEK*DEK proto-oncogene−3.006Nucleustranscription regulator  *DNAJB6*DnaJ (Hsp40) homolog, subfamily B, member 6−4.383Nucleustranscription regulator ETV5ets variant 5−2.163Nucleustranscription regulator  *KLF13*Kruppel-like factor 13−2.006Nucleustranscription regulator  *KLF6*Kruppel-like factor 66.003Nucleustranscription regulator  *NAA15*N(alpha)-acetyltransferase 15, NatA auxiliary subunit3.605Nucleustranscription regulator  *NFIX*nuclear factor I/X (CCAAT-binding transcription factor)−2.548Nucleustranscription regulator NFKB2nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)2.768Nucleustranscription regulator  *PA2G4*proliferation-associated 2G4, 38 kDa−2.702Nucleustranscription regulator PRDM2PR domain containing 2, with ZNF domain3.677Nucleustranscription regulator  *TBL1XR1*transducin (beta)-like 1 X-linked receptor 12.587Nucleustranscription regulator TCEB3transcription elongation factor B (SIII), polypeptide 3 (110 kDa, elongin A)3.053Nucleustranscription regulator CAMK1Gcalcium/calmodulin-dependent protein kinase IG−2.271Cytoplasmkinase  *CAMK2N1*calcium/calmodulin-dependent protein kinase II inhibitor 1−11.813Plasma Membranekinase  *CARD11*caspase recruitment domain family, member 117.343Cytoplasmkinase  *CDK11A*cyclin-dependent kinase 11A−4.29Nucleuskinase FGRFGR proto-oncogene, Src family tyrosine kinase3.915Nucleuskinase HCKHCK proto-oncogene, Src family tyrosine kinase3.887Cytoplasmkinase HSPB8heat shock 22 kDa protein 84.112Cytoplasmkinase LATS1large tumor suppressor kinase 12.003Nucleuskinase MAP4K4mitogen-activated protein kinase kinase kinase kinase 42.258Cytoplasmkinase NEK6NIMA-related kinase 62.322Nucleuskinase  *SRPK2*SRSF protein kinase 2−5.614Nucleuskinase TJP2tight junction protein 22.552Plasma Membranekinase Ccl2chemokine (C-C motif) ligand 2195.455Extracellular Spacecytokine CCL3L3chemokine (C-C motif) ligand 3-like 35.269Extracellular Spacecytokine CCL4chemokine (C-C motif) ligand 42.162Extracellular Spacecytokine Ccl6chemokine (C-C motif) ligand 610.291Extracellular Spacecytokine Ccl7chemokine (C-C motif) ligand 7124.78Extracellular Spacecytokine CXCL3chemokine (C-X-C motif) ligand 313.211Extracellular Spacecytokine Cxcl9chemokine (C-X-C motif) ligand 92.846Extracellular Spacecytokine  *TIMP1*TIMP metallopeptidase inhibitor 138.486Extracellular Spacecytokine IL6Rinterleukin 6 receptor2.315Plasma Membranetransmembrane receptor  *IL6ST*interleukin 6 signal transducer2.307Plasma Membranetransmembrane receptor ITGB2integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)2.675Plasma Membranetransmembrane receptor TLR4toll-like receptor 42.699Plasma Membranetransmembrane receptor TNFRSF1Atumor necrosis factor receptor superfamily, member 1A3.555Plasma Membranetransmembrane receptor UNC5Bunc-5 homolog B (C. elegans)2.067Plasma Membranetransmembrane receptor ALBalbumin−3.125Extracellular Spacetransporter  *LCN2*lipocalin 271.824Extracellular Spacetransporter  *RASA1*RAS p21 protein activator (GTPase activating protein) 12.392Cytoplasmtransporter  *TPR*translocated promoter region, nuclear basket protein2.212Nucleustransporter  *FGL2*fibrinogen-like 216.793Extracellular Spacepeptidase SENP2SUMO1/sentrin/SMT3 specific peptidase 22.051Nucleuspeptidase DUSP5dual specificity phosphatase 53.285Nucleusphosphatase  *PTPRF*protein tyrosine phosphatase, receptor type, F−6.365Plasma Membranephosphatase  *EIF3C*eukaryotic translation initiation factor 3, subunit C−4.369Othertranslation regulator  *EIF5B*eukaryotic translation initiation factor 5B−3.044Cytoplasmtranslation regulator FGF2fibroblast growth factor 2 (basic)2.387Extracellular Spacegrowth factor  *KCND2*potassium voltage-gated channel, Shal-related subfamily, member 2−2.792Plasma Membraneion channel  *AHI1*Abelson helper integration site 12.243Cytoplasmother BCL2A1BCL2-related protein A13.055Cytoplasmother CALB1calbindin 1, 28 kDa−2.091Cytoplasmother  *CD68*CD68 molecule4.365Plasma Membraneother CDCA7Lcell division cycle associated 7-like2.648Nucleusother  *CDT1*chromatin licensing and DNA replication factor 13.098Nucleusother  *CISD2*CDGSH iron sulfur domain 2−7.833Cytoplasmother  *CMIP*c-Maf inducing protein−3.778Cytoplasmother DAB2Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)3.053Plasma Membraneother DESdesmin2.857Cytoplasmother DNAJB9DnaJ (Hsp40) homolog, subfamily B, member 92.128Nucleusother FLNAfilamin A, alpha3.45Cytoplasmother  *GADD45G*growth arrest and DNA-damage-inducible, gamma3.191Nucleusother  *HLA-A*major histocompatibility complex, class I, A9.296Plasma Membraneother HSPA2heat shock 70 kDa protein 23.51Cytoplasmother  *LCP1*lymphocyte cytosolic protein 1 (L-plastin)6.082Cytoplasmother  *LSP1*lymphocyte-specific protein 111.716Cytoplasmother MMS22LMMS22-like, DNA repair protein2.918Nucleusother MSI2musashi RNA-binding protein 22.288Cytoplasmother PDLIM7PDZ and LIM domain 7 (enigma)4.695Cytoplasmother  *PHLDA1*pleckstrin homology-like domain, family A, member 15.129Cytoplasmother  *PMEPA1*prostate transmembrane protein, androgen induced 12.682Plasma Membraneother  *PSIP1*PC4 and SFRS1 interacting protein 1−2.663Nucleusother  *RDX*radixin4.828Cytoplasmother  *SERPINA3*serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 358.488Extracellular Spaceother SPIN1spindlin 12.178Nucleusother SUDS3suppressor of defective silencing 3 homolog (S. cerevisiae)2.228Nucleusother TAGLN2transgelin 23.891Cytoplasmother  *THOC2*THO complex 22.119Nucleusother TMEM109transmembrane protein 1092.106Cytoplasmother TMEM123transmembrane protein 1232.348Plasma Membraneother*Orphan*  *CYP1B1*cytochrome P450, family 1, subfamily B, polypeptide 110.998Cytoplasmenzyme  *KIF3A*kinesin family member 3A−5.083Cytoplasmenzyme PTGR1prostaglandin reductase 12.258Cytoplasmenzyme  *RND3*Rho family GTPase 32.864Cytoplasmenzyme WFS1Wolfram syndrome 1 (wolframin)2.083Cytoplasmenzyme ITPR2inositol 1,4,5-trisphosphate receptor, type 22.489Cytoplasmion channel  *KCNN4*potassium intermediate/small conductance calcium-activated channel, subfamily N, member 43.088Plasma Membraneion channel  *ATRX*alpha thalassemia/mental retardation syndrome X-linked2.091Nucleustranscription regulator RAI14retinoic acid induced 143.284Nucleustranscription regulator CX3CL1chemokine (C-X3-C motif) ligand 1−2.044Extracellular Spacecytokine PTGER3prostaglandin E receptor 3 (subtype EP3)2.425Plasma MembraneG-protein coupled receptor PI4K2Aphosphatidylinositol 4-kinase type 2 alpha2.96Cytoplasmkinase CD36CD36 molecule (thrombospondin receptor)5.08Plasma Membranetransmembrane receptor ARL11ADP-ribosylation factor-like 113.143Otherother  *Brd4*bromodomain containing 4−3.528Nucleusother CLN5ceroid-lipofuscinosis, neuronal 52.041Cytoplasmother  *Ctdspl*CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like−7.271Cytoplasmother  *KIFAP3*kinesin-associated protein 3−2.281Cytoplasmother  *Nos1ap*nitric oxide synthase 1 (neuronal) adaptor protein−2.698Otherother PCDH15protocadherin-related 152.147Plasma Membraneother  *RASSF4*Ras association (RalGDS/AF-6) domain family member 44.289Otherother  *Rbm25*RNA binding motif protein 25−5.547Nucleusother  *Slpi*secretory leukocyte peptidase inhibitor82.908Cytoplasmother  *Tpm3*tropomyosin 32.592Cytoplasmother  *TRIM54*tripartite motif containing 54−4.426CytoplasmotherPrimary: \>14 connections in GOI network (see text); Secondary: 8--14 connections in GOI network; Peripheral: \<8 connections in GOI network; Orphan: No connections in GOI network; Italics= \> Gene changes on both sides of the brain

TBI-C: A total of 115 GOI were identified. Our analysis showed that 78 of the GOI formed an interconnected network, leaving 37 "orphan" genes (see Additional file [5](#MOESM5){ref-type="media"}). Genes having 1st order connections with more than 10 % of the other genes within the main GOI network (\>8 connections) were considered "primary" in this analysis (see Fig. [9](#Fig9){ref-type="fig"} for an example). Genes having connections with 5 %--10 % of the other genes (4--8 connections) were considered "secondary" (see Additional file [6](#MOESM6){ref-type="media"} for an example) and those with connections with less than 5 % of the other genes (\<4 connections) were considered "peripheral". The resultant GIH is displayed in Table [7](#Tab7){ref-type="table"}.Fig. 9An example of calculating the number of direct connections for the TBI-C GOI network. In IPA, the gene in question was selected (SOX2 in this example). Then, its direct connections were selected by right clicking on SOX2 and using the "select nearest neighbors" option (highlighted in blue). A list of the selected genes was exported and SOX2 was removed from the list (upper right corner). The remaining genes were counted (13 in this example) and SOX2 was ranked in the TBI-C gene interaction hierarchy (primary tier) by this numberTable 7TBI-C Gene interaction hierarchy (GIH)Gene symbolEntrez gene nameFold changeCellular compartmentMolecular type*Primary*  *CCND1*cyclin D1−2.027Nucleustranscription regulator MED1mediator complex subunit 1−4.011Nucleustranscription regulator*SMARCA4*SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4−7.712Nucleustranscription regulator SOX2SRY (sex determining region Y)-box 2−4.791Nucleustranscription regulator SP1Sp1 transcription factor−2.076Nucleustranscription regulator  *STAT3*signal transducer and activator of transcription 3 (acute-phase response factor)−3.771Nucleustranscription regulator*CSNK2A1*casein kinase 2, alpha 1 polypeptide−2.75Cytoplasmkinase  *EGFR*epidermal growth factor receptor2.374Plasma Membranekinase  *GSK3B*glycogen synthase kinase 3 beta−6.635Nucleuskinase  *CD44*CD44 molecule (Indian blood group)2.399Plasma MembraneenzymeHSP90AA1heat shock protein 90 kDa alpha (cytosolic), class A member 1−4.843Cytoplasmenzyme*Secondary* FOXO1forkhead box O1−3.329Nucleustranscription regulator MEF2Amyocyte enhancer factor 2A−6.31Nucleustranscription regulator  *NFIX*nuclear factor I/X (CCAAT-binding transcription factor)−8.112Nucleustranscription regulator  *TCF4*transcription factor 4−4.625Nucleustranscription regulator MAPK8mitogen-activated protein kinase 82.102Cytoplasmkinase PIK3R2phosphoinositide-3-kinase, regulatory subunit 2 (beta)2.332Cytoplasmkinase PTK2Bprotein tyrosine kinase 2 beta2.15Cytoplasmkinase KRASKirsten rat sarcoma viral oncogene homolog−2.027Cytoplasmenzyme  *TOP2A*topoisomerase (DNA) II alpha 170 kDa−2.406Nucleusenzyme ATP2A2ATPase, Ca++ transporting, cardiac muscle, slow twitch 2−2.607Cytoplasmtransporter BAXBCL2-associated X protein−3.306Cytoplasmtransporter  *SPP1*secreted phosphoprotein 12.37Extracellular Spacecytokine  *THRA*thyroid hormone receptor, alpha−11.518Nucleusligand-dependent nuclear receptor TUFMTu translation elongation factor, mitochondrial−2.109Cytoplasmtranslation regulator CCND2cyclin D2−3.617Nucleusother  *HSPB1*heat shock 27 kDa protein 12.639Cytoplasmother*Peripheral*  *BTG2*BTG family, member 2−5.803Nucleustranscription regulator  *CCAR1*cell division cycle and apoptosis regulator 1−11.648Nucleustranscription regulator  *CEBPD*CCAAT/enhancer binding protein (C/EBP), delta2.037Nucleustranscription regulator  *DEK*DEK proto-oncogene−7.352Nucleustranscription regulator  *DNAJB6*DnaJ (Hsp40) homolog, subfamily B, member 65.614Nucleustranscription regulator GBX2gastrulation brain homeobox 22.59Nucleustranscription regulator  *KLF6*Kruppel-like factor 62.865Nucleustranscription regulator MAFGv-maf avian musculoaponeurotic fibrosarcoma oncogene homolog G−2.632Nucleustranscription regulator MTDHmetadherin−2.544Cytoplasmtranscription regulator  *PA2G4*proliferation-associated 2G4, 38 kDa−5.783Nucleustranscription regulator RSF1remodeling and spacing factor 1−2.618Nucleustranscription regulator  *TBL1XR1*transducin (beta)-like 1 X-linked receptor 1−2.134Nucleustranscription regulatorZMYND11zinc finger, MYND-type containing 11−2.211Nucleustranscription regulator ZNF148zinc finger protein 1482.114Nucleustranscription regulator ACIN1apoptotic chromatin condensation inducer 1−2.515Nucleusenzyme  *CYP1B1*cytochrome P450, family 1, subfamily B, polypeptide 14.808Cytoplasmenzyme DPYDdihydropyrimidine dehydrogenase2.292Cytoplasmenzyme MFN1mitofusin 12.304Cytoplasmenzyme  *MX1*MX dynamin-like GTPase 17.326Cytoplasmenzyme  *SETD8*SET domain containing (lysine methyltransferase) 8−3.93Nucleusenzyme TTLL1tubulin tyrosine ligase-like family, member 12.284Extracellular SpaceenzymeACVR1Cactivin A receptor, type IC−9.107Plasma Membranekinase  *CARD11*caspase recruitment domain family, member 112.892Cytoplasmkinase  *CDK11A*cyclin-dependent kinase 11A−14.872Nucleuskinase CDK19cyclin-dependent kinase 19−2.191Nucleuskinase PIK3CDphosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta−2.113Cytoplasmkinase PRKAA2protein kinase, AMP-activated, alpha 2 catalytic subunit−2.546Cytoplasmkinase  *SRPK2*SRSF protein kinase 2−23.589Nucleuskinase PPP3CBprotein phosphatase 3, catalytic subunit, beta isozyme2.1Plasma Membranephosphatase  *PTPRF*protein tyrosine phosphatase, receptor type, F−20.492Plasma Membranephosphatase  *IL6ST*interleukin 6 signal transducer−3.283Plasma Membranetransmembrane receptor PRLRprolactin receptor−3.192Plasma Membranetransmembrane receptor  *LCN2*lipocalin 23.895Extracellular Spacetransporter  *RASA1*RAS p21 protein activator (GTPase activating protein) 1−2.105Cytoplasmtransporter  *TIMP1*TIMP metallopeptidase inhibitor 12.101Extracellular Spacecytokine  *EIF5B*eukaryotic translation initiation factor 5B−8.766Cytoplasmtranslation regulator  *AHI1*Abelson helper integration site 1−2.897Cytoplasmother  *CDT1*chromatin licensing and DNA replication factor 1−2.295Nucleusother  *CISD2*CDGSH iron sulfur domain 2−19.012Cytoplasmother*GADD45G*growth arrest and DNA-damage-inducible, gamma−2.384Nucleusother  *HLA-A*major histocompatibility complex, class I, A3.657Plasma Membraneother LINGO1leucine rich repeat and Ig domain containing 1−2.173Plasma Membraneother MAFBv-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B−2.018Nucleusother  *PHLDA1*pleckstrin homology-like domain, family A, member 12.16Cytoplasmother  *PMEPA1*prostate transmembrane protein, androgen induced 1−2.937Plasma Membraneother  *PSIP1*PC4 and SFRS1 interacting protein 12.113Nucleusother RAD23BRAD23 homolog B (S. cerevisiae)−2.217Nucleusother  *RASSF4*Ras association (RalGDS/AF-6) domain family member 42.106Otherother  *RDX*radixin−5.274Cytoplasmother Serbp1Serpine1 mRNA binding protein 1−2.059Cytoplasmother*SERPINA3*serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 32.509Extracellular Spaceother*Orphan* AURKAIP1aurora kinase A interacting protein 1−2.023Nucleusenzyme  *CP*ceruloplasmin (ferroxidase)8.477Extracellular Spaceenzyme  *EHD4*EH-domain containing 4−2.056Plasma Membraneenzyme ENTPD5ectonucleoside triphosphate diphosphohydrolase 5−2.055Cytoplasmenzyme  *KIF3A*kinesin family member 3A−11.754CytoplasmenzymeNDUFAB1NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8 kDa−2.028Cytoplasmenzyme  *PDE4B*phosphodiesterase 4B, cAMP-specific2.359Cytoplasmenzyme  *RND3*Rho family GTPase 3−2.971Cytoplasmenzyme  *SDC1*syndecan 12.566Plasma Membraneenzyme  *SRXN1*sulfiredoxin 12.402Cytoplasmenzyme  *ATRX*alpha thalassemia/mental retardation syndrome X-linked−5.964Nucleustranscription regulator  *KLF13*Kruppel-like factor 13−4.582Nucleustranscription regulator  *NAA15*N(alpha)-acetyltransferase 15, NatA auxiliary subunit−3.751Nucleustranscription regulator  *KCND2*potassium voltage-gated channel, Shal-related subfamily, member 2−7.585Plasma Membraneion channel  *KCNN4*potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4−9.429Plasma Membraneion channel*CAMK2N1*calcium/calmodulin-dependent protein kinase II inhibitor 1−23.824Plasma Membranekinase TRPM7transient receptor potential cation channel, subfamily M, member 72.226Plasma Membranekinase ATP2B2ATPase, Ca++ transporting, plasma membrane 22.276Plasma Membranetransporter  *TPR*translocated promoter region, nuclear basket protein−2.728Nucleustransporter  *FGL2*fibrinogen-like 24.017Extracellular Spacepeptidase  *EIF3C*eukaryotic translation initiation factor 3, subunit C−9.072Othertranslation regulator  *Brd4*bromodomain containing 4−15.202NucleusotherCCDC86coiled-coil domain containing 86−2.149Nucleusother  *CD68*CD68 molecule2.007Plasma Membraneother CDH13cadherin 13−2.692Plasma Membraneother  *CMIP*c-Maf inducing protein−13.763Cytoplasmother  *Ctdspl*CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like−36.886Cytoplasmother  *KIFAP3*kinesin-associated protein 3−7.831Cytoplasmother  *LCP1*lymphocyte cytosolic protein 1 (L-plastin)2.799Cytoplasmother  *LSP1*lymphocyte-specific protein 12.14Cytoplasmother  *Nos1ap*nitric oxide synthase 1 (neuronal) adaptor protein−5.717Otherother PALLDpalladin, cytoskeletal associated protein−5.086Plasma Membraneother  *Rbm25*RNA binding motif protein 25−16.213Nucleusother  *Slpi*secretory leukocyte peptidase inhibitor3.119Cytoplasmother  *THOC2*THO complex 2−4.886Nucleusother  *Tpm3*tropomyosin 3−2.715Cytoplasmother  *TRIM54*tripartite motif containing 54−2.032CytoplasmotherPrimary: \>8 connections in GOI network (see text); Secondary: 4--8 connections in GOI network; Peripheral: \<4 connections in GOI network; Orphan: No connections in GOI network; Italics= \> Gene changes on both sides of the brain

Cell cycle genes included in the GIHs {#Sec18}
-------------------------------------

We performed an IPA molecular and cellular functional analysis on the unranked GOI for both datasets and the top 2 tiers (most significant by our definition) of our resultant GIHs to further elucidate the most significant biological functions post-TBI (Fig. [10](#Fig10){ref-type="fig"}). The cell death and survival category was removed from this analysis since all genes were initially selected from this functional category. When analyzing the top 2 tiers of the GIHs, cell cycle was ranked second for TBI-I and first for TBI-C. Is was also the highest ranked molecular and cellular function common to both sides (Fig. [10](#Fig10){ref-type="fig"}[b](#Fig10){ref-type="fig"}, [d](#Fig10){ref-type="fig"}). The cell cycle moved up 5 functional ranking spots on both sides of the brain from where it was ranked prior to the GIH analysis. This result was intriguing because aberrant attempts to reactivate the cell cycle by post-mitotic neurons have been implicated as a trigger for apoptosis \[[@CR26], [@CR27]\]. By cross-referencing our GIHs with genes that IPA includes in the cell cycle upper level biological function, we determined that 74 genes in the TBI-I GIH and 47 genes in the TBI-C GIH were associated with the cell cycle (Tables [8](#Tab8){ref-type="table"} and [9](#Tab9){ref-type="table"}). Just over 85 % of the cell cycle genes increased in expression ipsilaterally compared to controls. The relative inverse is true contralaterally with nearly 79 % of the cell cycle genes decreasing in expression. Remarkably, 83 % of TBI-I and 70 % of TBI-C primary and secondary tier genes were classified as cell cycle genes (TBI-I: 35 of 42 genes; TBI-C: 19 of 27 genes).Fig. 10Functional analysis of GOI and top 2 GIH tiers. The top 10 molecular and cellular functions determined by IPA to be associated with the unranked GOI for TBI-I (**a**) and TBI-C (**c**) and the primary and secondary tiers of the TBI-I (**b**) and TBI-C (**d**) GIHs. Side by side comparison allowed for visualization of how functions changed in significance order once the genes were put into a ranked order. Notably, cell cycle moved up to be ranked second on both sides of the brain. *The cell death and survival category was removed from this analysis because all genes were initially selected from that functional category*Table 8Cell cycle genes in the TBI-I gene interaction hierarchy by tierPrimarySecondaryPeripheralOrphanATF3BAG3BCL2A1NEK6ATRXCASP3CASP7BTG2NFIXBrd4CCND1CCNA2CAMK2N1PA2G4CYP1B1CD44CDKN1BCcl2PDLIM7CDK1CEBPDCDK11APMEPA1CEBPBCREMCDT1PRDM2CREB1FOSL1DEKPTPRFCREBBPHSPA1A/HSPA1BETV5RAB35CSNK2A1HSPB1FGF2SETD8EGFRIKBKBFLNASRPK2ELAVL1IL1BGADD45GSUDS3FN1KLF4HMOX1TBL1XR1GSK3BKPNB1HSPA2TCEB3MDM2MCL1IL6RTHOC2NFE2L2MCM2KLF6TIMP1SMARCA4MITFLATS1TNFRSF1ASTAT3PTGS2MCM8TOP2ASPP1MMS22LTPRTable 9Cell cycle genes in the TBI-C gene interaction hierarchy by tierPrimarySecondaryPeripheralOrphanCCND1BAXACIN1MTDHATRXCD44CCND2BTG2PA2G4Brd4CSNK2A1FOXO1CDK11APMEPA1CAMK2N1EGFRHSPB1CDK19PRKAA2CDH13GSK3BKRASCDT1PTPRFENTPD5SMARCA4MAPK8CEBPDRSF1THOC2SOX2NFIXCYP1B1SETD8TPRSP1PTK2BDEKSRPK2STAT3SPP1GADD45GTBL1XR1TOP2AKLF6TIMP1MAFB

Real-time PCR {#Sec19}
-------------

As expected, ipsilateral expression was significantly increased compared to naïve for all genes tested following TBI (Fig. [11](#Fig11){ref-type="fig"}). However, ipsilateral expression was only significantly different from contralateral expression for SPP1 and HSPB1 while this comparison for STAT3 (*p =* 0.088) and CCND1 (*p =* 0.063) fell short of statistical significance. Contralateral expression was not significantly different from naïve for any of the genes tested.Fig. 11Real-time PCR results for selected genes. SPP1, HSPB1, STAT3, and CCND1 were chosen for real-time PCR studies. Using the ΔΔCt method, the normalized target gene expression level was given by 2^-ΔΔCt^. For all genes, ipsilateral (IPSI) expression was significantly different from naïve (**a**-**d**). Ipsilateral expression was also significantly different from contralateral (CONTRA) expression for SPP1 (**a**) and HSPB1 (**b**). The comparison of ipsilateral to contralateral expression for STAT3 (**c**; *p =* 0.088) and CCND1 (**d**; *p =* 0.063) fell short of statistical significance. Contralateral expression was not significantly different from naïve for any genes. *The results are shown as mean ± SE. \* p \< 0.05, \*\* p \< 0.01, \*\*\* p \< 0.005*

Discussion {#Sec20}
==========

We used microarray technology and subsequent bioinformatic analysis in this study to examine molecular and functional alterations following TBI. Not surprisingly, cell death and survival was determined to be a significant molecular and cellular function associated with the genes expressed ipsilateral to the injury. Interestingly, while cell death was not observed on the contralateral side of the brain, there was significant modulation of cell death and survival genes and this molecular and cellular function is very highly associated with the gene expression pattern.

Our histology results using markers for cell damage (FJB) and DNA fragmentation (TUNEL) suggest a potential opportunity for therapeutic intervention. At 24 h post-injury, there is a developing cortical cavity at the site of impact surrounded with FJB and TUNEL-positive cells. Therapy aimed at preserving cortical tissue should be administered in the acute period to exert maximal neuroprotective effects. However, while there is significant correlation between FJB and TUNEL staining in the cortex at this time point, no TUNEL-positive cells were detected in the hippocampus where FJB detected some neuronal damage on the ipsilateral side. Similar histology results were recently seen with our model of nerve agent exposure \[[@CR20]\] and a neuroprotective agent was able to rescue the hippocampal neurons \[[@CR28]\]. This suggests that these hippocampal neurons have not yet progressed to the point of apoptosis and an extended therapeutic window may exist for subcortical brain areas.

Our microarray data showed that TBI resulted in significant alterations in CD gene expression on both sides of the brain. Nearly 45 % of the differentially expressed CD genes were common to both sides of the brain and 82 % of those genes changed similarly. However, a distinct expression pattern was exhibited by the balance of the common CD genes and those that change in expression uniquely on one side of the brain. The vast majority of these ipsilateral CD genes increased in expression compared to controls, while the majority of these contralateral CD genes decreased in expression compared to controls or were reduced compared to ipsilateral expression. Notable was the expression of key apoptosis-related genes. BCL2A1, caspases 3 and 7, CDK1, cyclins A2 and D1, and NFKB2 showed increased expression ipsilaterally, while BAX, cyclins D1and D2, KRAS and PIK3CD showed decreased expression contralaterally.

It is important to note here that the real-time PCR results for the genes selected did not agree totally with the microarray results. This was especially true for the contralateral samples. However, it has been shown that the correlation between microarray and real-time PCR results is lower for genes showing decreased expression and having lower fold changes \[[@CR29]\]. Our results do show better correlation with the large TBI-I fold change genes SPP1 (37.9 fold) and HSPB1 (46.9 fold). The remaining fold changes for the selected genes are less than ± 4.22 with most in the 2.0-2.6 range. While further validation including more genes and a larger sample size may be needed for subsequent studies, these PCR results are consistent with expression of these genes being higher for TBI-I and lower for TBI-C. It is in this context that the discussion of the microarray results continues.

As stated above, this contralateral expression pattern in our model may indicate an endogenous effort to suppress cell death promoting genes remote from the injury in order to prevent spreading of the injury and offer additional protection from additional insults, similar to gene expression changes in ischemic preconditioning \[[@CR30], [@CR31]\]. An analogous and potentially neuroprotective gene expression pattern was observed in an *in vitro* model of mild TBI where the modulation of genes reflected an endogenous effort to prevent oxidative/nitrosative stress and apoptosis during a transient period of mitochondrial malfunctioning \[[@CR32]\]. We have previously reported a similar gene expression pattern for inflammatory response genes following TBI \[[@CR12]\]. In that previous study, genes from both sides of the brain were pooled for analysis. Because we now believe that analyzing gene expression on the contralateral side is critical to understanding endogenous protective mechanisms, the full GIH analysis \[[@CR33]\] was performed on each side of the brain separately. By determining the key molecules involved in the endogenous effort to suppress cell death, it may be possible to develop molecular strategies to provide neuroprotection for the injured brain as well as augment the endogenous neuroprotective process.

We identified 170 TBI-I and 115 TBI-C GOI through canonical pathway and network analysis combined with the common genes that change differently on each side of the brain. Many of these genes have been previously associated with acute brain injuries (i.e., TBI, stroke) but not all of them have been connected to the cell death caused by these injuries. These genes include BAX, CASP3, CCNA2, CCND1, CD44, CD68, CEBPD, GSK3B, HSPB1, IL1B, LCN2, NFKB2, SERPINA3, SPP1, STAT3, TIMP1, TNFRSF1A, and TOP2A \[[@CR14], [@CR34]--[@CR42]\]. This supported the idea that our methods for identifying genes of interest targets important genes in the post-injury response. Several genes which have been linked to cell death in cancer, epilepsy, or psychological disorders but not yet associated with brain injury, including CSNK2A1, ELAVL1, MITF, and SMARCA4, were also identified which may provide additional therapeutic targets for prevention of cell death following TBI. We next wanted to determine which genes were central to cell death processes. We approached this by creating a network of our GOI within IPA and determining how many 1st order connections each gene had with the other genes in the network. A GIH was created based on these numbers and distinct patterns in terms of molecular type were found.

For TBI-I, transcription regulators were the predominant molecular type in the top 2 tiers of the GIH. This result was expected from our previous GIH analyses \[[@CR12]\]. After the transcription regulators, kinases and unspecified enzymes were prominent in the top 2 tiers of the TBI-I GIH. In the peripheral tier, unspecified enzymes, transcription regulators and kinases were most represented. Cytokines, transmembrane receptors, and transporters also had notable numbers in the peripheral tier. Remarkably, only 2 cytokines, IL1B and SPP1, are included in the top 2 tiers of this GIH. This result is not unexpected as previous GIH analysis had shown that the near 1-to-1 relationship that cytokines have with their receptors limits the 1st order connections these molecules have in the GOI network \[[@CR12]\].

Transcription regulators were also predominant in the top 2 tiers of the TBI-C GIH followed by kinases and unspecified enzymes. These same molecular types headed the peripheral tier as well with transcription regulators ahead of enzymes and kinases. Other notable molecular types in the peripheral tier were phosphatases, transmembrane receptors, and transporters. Again, cytokines do not have significant numbers in this GIH. Our analysis strongly suggests that other molecular types, transcription regulators, kinases, and other enzymes in this case, may be better therapeutic targets because they have the potential to impact the overall cell death process to a greater extent.

Very intriguing in our cell death analysis was how cell cycle moved up significantly in functional ranking on both sides of the brain when comparing the functional analysis for unranked GOI to that for the top 2 tiers of our GIHs. Cell cycle molecules have be implicated as apoptotic mediators for post-mitotic cells under stress due to trauma or neurological disease. It is believed that there is an aberrant attempt the re-enter the cell cycle that causes the cells to eventually undergo apoptosis \[[@CR26], [@CR43]--[@CR48]\]. Much attention has been given to the cyclin-dependent kinases (CDKs), cyclins, which activate the CDKs \[[@CR27], [@CR48], [@CR49]\], and CDK inhibitors. Significant evidence for CDK involvement in cell cycle-related apoptosis has come from the experimental use of exogenous CDK inhibitors that prevented apoptosis \[[@CR47], [@CR50]--[@CR56]\]. Pertinent to this discussion, evidence has shown that CDK1, when activated by cyclin A \[[@CR57]\], and CDK4 and CDK6, when activated by cyclin D in post-mitotic neurons, can lead to cell death via caspase-dependent apoptosis \[[@CR26], [@CR27], [@CR44], [@CR49]\]. Additionally, ablation of cyclin D1 reduces neurodegeneration caused by TBI \[[@CR58]\]. CDK11 has been shown to initiate apoptosis by interacting with either cyclin D3 \[[@CR59]\] or eukaryotic translation initiation factor 3 subunit F (EIF3F) \[[@CR60]\]. In our model, cyclins A2 and D1 are increased ipsilaterally, consistent with other studies \[[@CR27], [@CR47], [@CR50]\], while both cyclins D1 and D2 are decreased contralaterally. CDK1 and the CDK4 inhibitors, CDKN1A (p21,Cip1 (not in GIH)) and CDKN1B (p27,Kip1), are all increased ipsilaterally. CDK11 (CDK11A (both sides); CDK19 (TBI-C only)) decreases in expression on both sides of the brain. While not found in our analysis, EIF3F is part of the functional core of EIF along with EIF3A (TBI-C only (not in GIH)) and EIF3C (both sides) which decrease in expression following TBI \[[@CR61]\]. It is plausible that apoptosis would occur in this injury state because these molecules are not being expressed in the tightly controlled manner necessary to properly navigate the cell cycle \[[@CR46], [@CR55]\]. Other CDKs have also been implicated in apoptosis and excitotoxic cell death \[[@CR26], [@CR49], [@CR51], [@CR52], [@CR62], [@CR63]\] but our GIH does not point to those as major players.

In addition to 4 TBI-I and 2 TBI-C CDK-related genes, IPA classified 31 other TBI-I genes and 17 other TBI-C genes in the top 2 tiers of their respective GIHs as cell cycle genes. It should be noted that cell cycle is an upper level function in IPA. That means these genes, while associated with the cell cycle, are not necessarily integral to its progression. These genes fell into 3 general categories. The first category included those genes that have been experimentally linked to a model of TBI. Genes in this category were ATF3, BAG3, CASP3, CASP7, CD44, CEBPB, CEBPD, CREB1, CREM, EGFR, FN1, FOSL1, GSK3B, HSPA1A/HSPA1B, HSPB1, IKBKB, IL1B, KLF4, MCL1, MDM2, NFE2L2, PTGS2, SPP1, and STAT3 for TBI-I \[[@CR22], [@CR36], [@CR40]--[@CR42], [@CR64]--[@CR78]\] and BAX, CD44, EGFR, FOXO1, GSK3B, HSPB1, MAPK8, SOX2, SPP1, and STAT3 for TBI-C \[[@CR22], [@CR36], [@CR40], [@CR41], [@CR67], [@CR71], [@CR78]--[@CR81]\]. The second category included genes that had been observed in models of hypoxia/ischemia, chemical brain lesions, or spinal cord injury. Genes in this category were CREBBP and KPNB1 for TBI-I \[[@CR82], [@CR83]\] and KRAS, PTK2B, SP1, and TOP2A for TBI-C \[[@CR84]--[@CR87]\]. The third category included genes that were previously linked only to the progression of cancers or psychotic disorders and, therefore, novel to a discussion of cell death following TBI. Genes in this category were CSNK2A1, ELAVL1, MCM2, MITF, and SMARCA4 for TBI-I and CSNK2A1, NFIX, and SMARCA4 for TBI-C. The specifics of how these genes are associated with the cell cycle and affect cell death are beyond the scope of this analysis. However, our GIH analysis would suggest that these genes would be intriguing targets for further study in relation to post-TBI cell death. Specifically, CCND1, CSNK2A1, SMARCA4, and STAT3 were included in the top 2 tiers for both datasets and exhibit increased expression in TBI-I and decreased expression in TBI-C. Additionally, cyclin D2 and 2 apoptosis signaling genes, BAX and KRAS, are in the secondary tier of the TBI-C GIH and show decreased expression. Targeting these key molecules showing contralateral suppression for potential therapies may prove effective because their expression correlates to the observed absence of cell death.

Conclusions {#Sec21}
===========

Unilateral TBI results in significant gene expression changes on both sides of the brain. The overall gene expression pattern in the brain suggests a suppression of CD genes contralateral to the injury which may be an endogenous protective mechanism. Using canonical pathways and IPA generated networks as a guide, we were able to identify genes that were central to the post-TBI CD gene response. Further network analysis allowed for the ranking of these genes into GIHs. The GIH ranking then led to the identification of cell cycle as a key molecular and cellular function on both sides of the brain. Significantly, several cell cycle molecules were identified in this analysis that exhibit increased expression ipsilaterally and decreased expression contralaterally. GIH analysis relies on connections in a virtual network. Future experiments will use discrete microdissected portions of the brain (cortex, hippocampus, striatum) in order to increase the likelihood that the molecular interactions described in the network actually do occur *in vivo*. This will increase the power of the GIH analysis. Further real-time PCR confirmation will be necessary with an emphasis on contralateral and decreased gene expression. Also, proteomic confirmation will be necessary to show that *in vivo* protein levels match our microarray results \[[@CR88], [@CR89]\]. Once confirmed, the key CD molecules suggested by our GIH can be further explored. Additional exploration into the remote suppression of CD genes may provide insight into neuroprotective mechanisms that could be used to develop therapies to prevent cell death following TBI.

Additional files {#Sec22}
================

Additional file 1:**Examples of** **TBI-I** **networks.** TBI-I CD networks 1 (A), 3 (B), 5 (C), and 6 (D) (see Table [2](#Tab2){ref-type="table"}) with all gene families, groups and complexes expanded to show the member genes and showing the relative expression values of potential GOI for TBI-I. *red: relative increase in expression; green: relative decrease in expression; white: no change in expression; gold connections and outlines: expansion of gene families, groups and complexes in the original network. (TIF 4.06 mb)*Additional file 2:**Examples of** **TBI-C** **networks.** TBI-C CD networks 1 (A), 3 (B), 5 (C), and 6 (D) (see Table [3](#Tab3){ref-type="table"}) with all gene families, groups and complexes expanded to show the member genes and showing the relative expression values of potential GOI for TBI-C. *red: relative increase in expression; green: relative decrease in expression; white: no change in expression; gold connections and outlines: expansion of gene families, groups and complexes in the original network. (TIF 4.30 mb)*Additional file 3:**The** **TBI-I** **GOI network.** This is the resultant network when IPA connected our 170 TBI-I GOI using only direct (1st order) connections between the genes. 145 of the GOI formed an interconnected network, leaving 25 "orphan" genes. (TIF 4.20 mb)Additional file 4:**An example of calculating the number of direct connections for the** **TBI-I** **GOI network.** In IPA, the gene in question was selected (HSPB1 in this example). Then, its direct connections were selected by right clicking on HSPB1 and using the "select nearest neighbors" option (highlighted in purple). A list of the selected genes was exported and HSPB1 was removed from the list (upper right corner). The remaining genes were counted (11 in this example) and HSPB1 was ranked in the TBI-I gene interaction hierarchy (secondary tier) by this number. (TIF 3.99 mb)Additional file 5:**The** **TBI-C** **GOI network.** This is the resultant network when IPA connected our 115 TBI-C GOI using only direct (1st order) connections between the genes. 78 of the GOI formed an interconnected network, leaving 37 "orphan" genes. (TIF 4.84 mb)Additional file 6:**An example of calculating the number of direct connections for the** **TBI-C** **GOI network.** In IPA, the gene in question was selected (CCND2 in this example). Then, its direct connections were selected by right clicking on CCND2 and using the "select nearest neighbors" option (highlighted in purple). A list of the selected genes was exported and CCND2 was removed from the list (upper right corner). The remaining genes were counted (6 in this example) and CCND2 was ranked in the TBI-C gene interaction hierarchy (secondary tier) by this number. (TIF 4.69 mb)
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